News on proteomics applications for clinical use in genetics, genomics, and molecular diagnostics.
With Medicare coverage for the test in place, the company is hoping it will surpass the limited commercial success of its initial Xpresys Lung offering.
A review by Max Planck researcher Matthias Mann and colleagues suggests that improved mass spec performance could enable more effective plasma marker discovery.
Johns Hopkins researchers added protein analysis to circulating tumor DNA testing to better detect early-stage pancreatic cancer.
The organization named the institutions that will be performing the proteomic and proteogenomic analyses planned to for the five-year, $65 million effort.
With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms.
